Genetics

This post covers four recent papers that use genetic instruments to ask which metabolites act on MS rather than merely accompany it. It follows the BMC Medicine metabolome-wide scan of roughly 1,300 metabolites and ratios across eight brain disorders, where uridine and dihydroorotate raised MS risk, adipoylcarnitine came out protective, and the follow-up checks (leave-one-out, MR-BMA, colocalization, polygenic scores) trimmed the result as much as they confirmed it. It then sets two independent mediation MR studies side by side, one finding six serum metabolites carrying 3.9 to 16.5 percent of an interleukin-7 effect and the other finding no mediation at all through cerebrospinal fluid metabolites, and notes what the authors themselves ask for next. It closes on the Nature Immunology study that deletes Arg1 in myeloid cells, which is the forward version of the same question.